Chronic lymphocytic leukemia (CLL) represents a perfect example of a human malignancy caused by an imbalance between proliferation and programmed cell death (PCD) . 1 This disease is characterized by the accumulation of monoclonal B cells (CD20 þ , CD5 þ and CD23 þ ) in the peripheral blood, bone marrow and secondary lymphoid organs. 2 CLL was initially considered as a disease deriving from an inherent defect in PCD. However, more recent studies suggest that accumulation of CLL cells could be a consequence of excessive proliferation, defective PCD or deregulation in proliferation/ PCD ratios. 1 The unraveling of the molecular mechanisms controlling PCD in CLL will therefore provide (i) a better understanding of the disease and (ii) a rationale for the development of specific drugs that modulate pathological PCD. Although PCD has traditionally been equated with caspase activation and with apoptosis, it is now accepted that nonapoptotic, non-caspase-dependent forms of PCD exist in immune system cells. 3 Indeed, the cell can use three mechanisms/pathways to accomplish its proper demise. These pathways are defined as type I, type II or type III PCD. 4 Type I PCD, or classical apoptosis, is caspase-dependent. Type II PCD is characterized by the appearance of autophagic vacuoles and seems not to be related to caspases. Type III PCD is caspaseindependent and occurs without pronounced nuclear chromatin condensation. The molecular pathways incriminated in this last type of PCD are poorly understood.
A recent study from our laboratory represents one of the first steps in the description of the molecular mechanisms controlling type III PCD in CLL. 5 In this study, we reported that the engagement of CD47 efficiently killed CLL cells. CD47 is a glycoprotein composed of a single IgV-like extracellular domain, a transmembrane region and a short intracytoplasmic tail. 6 CD47 functions both as a receptor for thrombospondin and as a ligand for the transmembrane signal regulatory proteins SIRP-a and SIRP-g. These molecules regulate a variety of biological phenomena in the immune system, such as platelet activation, leukocyte and dendritic cell migration, macrophage multinucleation and cell death. Concerning PCD, we reported in our recent paper that CD47-mediated type III PCD is exclusively characterized by cytoplasmic hallmarks, 5 including an exposure of phosphatydilserine in the outer leaflet of the plasma membrane, a decrease in mitochondrial transmembrane potential (DC m ) and reactive oxygen species production. Caspase-independent type III PCD involves the serpases, a family of serine proteases, and is related to the mitochondrial redeployment of the cytosolic protein Drp1. This protein is thus a key mediator of type III PCD. Our above-mentioned findings showed that type III PCD is a highly regulated caspase-independent cell death pathway in CLL. But, is it possible to modulate pathological PCD in CLL using this alternative cell death pathway? Indeed, is it conceivable to use the type III PCD effector Drp1 in the enhancement of the cell death response observed in CLL? Using a pharmacological approach, the aim of this study was to Figure 1 The effect of typical caspase-independent inhibitors on CD47-mediated type III programmed cell death (PCD). (a) Peripheral blood was collected from chronic lymphocytic leukemia (CLL) patients, and B cells were purified and cultured as described elsewhere. 5 To induce CD47-mediated type III PCD, cells were cultured during 1 h on pre-coated plates with CD47 mAb (monoclonal antibody) (5 mg/ml, clone B6H12). For inhibition assays, geldanamycin, 3-methyladenine (3-MA), bafilomycin A1, DPQ, DHIQ, PJ-34, arachidonyl trifluoromethyl ketone (AACOCF3), N-acetylcysteine (NAC), trolox, Mn(III) tetra(4-benzoic acid) porphyrin chloride (MnTBAP), glutathione monoethyl ester (GSH-MEE), z-FA.fmk, z-FY.fmk, pepstatin A, CA-074, calpeptin, Ac-LLM-CHO, PD150606, PD151746, lactacystin, MG-115, MG-132, NLVS and necrostatin-1 were added 30 min before CD47-triggering. PCD (measured as phosphatidylserine (PS) exposure) was analyzed by flow cytometry in a FACScalibur (BD Biosciences, Le-Pont-de-Claix, France) with the help of Annexin V-APC (5 ml per test; BD Biosciences). Table compiles (f) Drp1 mitochondrial redeployment was detected by immunoblotting. CLL cells were left untreated, treated with CD47 mAb for 1 h or pre-incubated with 3-MA before being treated with CD47 mAb. Cells were subjected to subcellular fractionation, and mitochondrial and cytosolic fractions were blotted for Drp1 immunodetection as described. 5 Fractionation quality and protein loading were verified by distribution of the specific subcellular markers: Cox IV (Invitrogen) for mitochondria and tubulin (Sigma-Aldrich) for the cytosol. examine these issues. This approach elucidated an unexpected connection between the two supposedly different caspaseindependent PCD pathways, type II and type III PCD, and confirmed that it is possible to enhance PCD response in CLL by means of Drp1 mitochondrial redeployment.
To address whether type III PCD could be modulated in CLL, we first tested the effect of typical caspase-independent inhibitors on the responsiveness of CLL cells to CD47 triggering. Our working hypothesis is the existence of a crosstalk between the different caspase-independent PCD mediators. 3 This being the case, among the large panel of inhibitors tested, including inhibitors of receptor-interacting protein, type II PCD (autophagy), poly(ADP-ribose)polymerase, cytosolic phospholipase A 2 , reactive oxygen species, cathepsins, calpains, proteasome and necroptosis, only 3-methyladenine (3-MA), a typical inhibitor of the autophagic type II PCD, blocked type III PCD (Figure 1a) . It is important to note that 3-MA precluded type II PCD at an early sequestration stage by the blockage of class III PI3K (phosphatidylinositol 3-phosphate kinase). In contrast, bafilomycin A 1 , which also blocks autophagic PCD, but at a later endosomal acidification stage (by inhibition of vacuolartype H þ -ATPase), failed to preclude type III PCD. This outcome strongly suggests the common implication of class III PI3K in type II and type III PCD.
We next sought to integrate the modulation of CD47-mediated PCD by 3-MA with our earlier reported data on type III PCD. Thus, we established that 3-MA blocked all the known hallmarks of CD47-mediated killing, including exposure of phosphatidylserine (Figure 1b) , DC m loss (Figure 1c) , reactive oxygen species production (Figure 1d ), serpases activation ( Figure 1e ) and Drp1 redistribution from cytosol to mitochondria (Figure 1f) . Thus, as in the case of type II PCD, 3-MA seems to Letters to the Editor regulate type III cell death at an early stage, upstream of the mitochondrial damage characterizing this kind of death. 5, 7 Altogether, this part of our study provides a first time evidence of a crosstalk between type II and type III PCD. Importantly, the identification of new modulators of type III PCD, such as 3-MA, might pave the way for novel pharmacological strategies against the pathological PCD characterizing CLL.
The second part of this letter addresses the potential use of Drp1 as a pharmacological tool in the improvement of the cell death response observed in CLL. In agreement with our earlier published results, 5 the enhancement of Drp1 redistribution from the cytosol to mitochondria is expected to provoke an irreversible damage in CLL. To validate this possibility, we first showed, by means of a biochemical approach, the physical association between Drp1 and cytoskeleton in CLL. In fact, Drp1 was easily immunodetected in cytoskeleton-enriched fractions from control cells, but only detected as a faint band in extracts from CD47-treated cells (Figure 2a ). This result indicates that the Drp1-cytoskeleton link was disturbed after CD47 triggering. Thus, the interference in the Drp1-cytoskeleton binding could be utilized in the enhancement of Drp1 redistribution from the cytosol to mitochondria. To this end, we used a peptide (DyIP), which, acting as a competitive inhibitor of dynamins and their associated-cytoskeleton proteins, 8 facilitates Drp1 redistribution. As expected, treatment of CLL with DyIP, followed by incubation on CD47 mAb (monoclonal antibody), increased both the redistribution of Drp1 to the mitochondria (Figure 2b ) and the observed mitochondrial damage (measured as DC m loss in Figure 2c ). This process was caspase-independent ( Figure 2d) .
Finally, we assessed whether the enhancement of Drp1 mitochondrial redeployment by means of DyIP was type III PCD-specific or, in contrast, whether it was possible to modulate the Drp1 cytosolic/mitochondrial redistribution and PCD in other forms of cell death (for example, classical type I PCD). To this end, we pretreated CLL cells with DyIP, followed by incubation with hydrocortisone (HC), a typical type I PCD apoptotic inductor, and assessed both the redistribution of Drp1 to the mitochondria and mitochondrial damage. As shown in Figure 2b , DyIP failed to enhance Drp1 redistribution after HC treatment. Consequently, no increase in mitochondrial damage was recorded (Figures 2c and d) . These results indicate that DyIP works specifically in the Drp1-dependent type III PCD pathway (Figures 2b-d) . Strikingly, enhancement of type III PCD through the promotion of Drp1 redistribution induced cell death in B cells from the 40 CLL patients tested. Indeed, DyIP pretreatment increased CD47-mediated mitochondrial damage and PCD, even in CLL cells with low response to HC treatment (Figures 2e  and f, group 2) . Induction of type III PCD and promotion of Drp1 redistribution by DyIP is thus an efficient means of inducing PCD in CLL.
Chronic lymphocytic leukemia relapsed after conventionaldose therapies. However, in a significant number of patients, the disease did not respond to these agents. Moreover, prolonged exposure led to the development of resistance and a progressive outcome. Expected goals in CLL research are thus the identification of new factors sustaining the lifespan of the malignant B cells, and the subsequent development of therapeutic agents that interfere/inhibit/modulate these molecules to regulate cell death. Our new data confirm that, in CLL, PCD is more complex than the analysis of caspase-dependent type I PCD mechanisms has been originally suggested. Indeed, PCD has diverse morphological appearances reflecting multiple biochemical pathways. In this sense, this letter confirms that, similar to apoptotic type I PCD, type III PCD could be modulated. Importantly, this alternative PCD program can occur in cells possessing a defective mechanism of apoptotic cell destruction (for example, HC-mediated PCD). This implies the existence of a type III PCD signaling pathway that could be modulated independent of the classical apoptotic pathway. Therefore, the combination of caspase-directed and alternative therapies based on targeting caspase-independent type III PCD effectors (for example, Drp1) offers a new rational approach to regulate pathological PCD in CLL.
Despite the marked morphological differences characterizing caspase-independent type II and type III PCD, 4 our study revealed that their molecular regulation could be intimately connected. From a PCD standpoint, this indicates that these two ways to die could be different facets of a similar cell death pathway rather than completely separate processes. In this sense, the unraveling of the mechanisms governing type III PCD lead to a better comprehension of PCD in CLL.
